Rugonersen Development Update: First Participant Dosed in the Phase 3 BEACON Trial

“We are deeply grateful to the participant and family who chose to take this first step, as well as to the investigators, study teams, and patient organizations whose partnership has made this possible.” said Brenda Vincenzi, M.D., chief medical officer, Oak Hill Bio.

Read the community letter

If you have questions about trial sites or participation, visit the BEACON study website: https://www.angelmanbeaconstudy.com/